Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
about
ALK Signaling and Target Therapy in Anaplastic Large Cell LymphomaAnaplastic lymphoma kinase: signalling in development and diseaseEvaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitorsThe MET axis as a therapeutic target.Clinical use of crizotinib for the treatment of non-small cell lung cancerThe biology and treatment of EML4-ALK non-small cell lung cancerThe role of the ALK receptor in cancer biologyRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCTargeted immunotherapy for pediatric solid tumorsCrizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancerThe Evolution of Therapies in Non-Small Cell Lung CancerTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughALK and ROS1 as a joint target for the treatment of lung cancer: a reviewEmerging importance of ALK in neuroblastomaReview of the current targeted therapies for non-small-cell lung cancerTargeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastomaProtein kinase inhibitors against malignant lymphomaCIViC databaseThe R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase7,8-Dichloro-1-oxo-β-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding ModesEML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancersCrizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.The role of HGF/c-MET signaling pathway in lymphomaPersonalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome itPersonalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinibInhibitors of the anaplastic lymphoma kinaseALK and NSCLC: Targeted therapy with ALK inhibitorsUnderstanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule InhibitorsTargeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic HypogonadismStable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK CellsClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKMET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
P2860
Q21129306-5999D325-C516-4BC2-809D-4A6661BA5699Q24312329-06E87A4D-36C8-46C6-A54E-AA1111A10E7AQ24595585-2CE6124E-C4EB-429B-81AB-1700783E724BQ24609682-95E15311-50F4-4E7F-93A3-4620B5157176Q24630466-4D0EDEF4-45EE-481B-8745-8BC30A1245DCQ24632625-44859761-6C83-4605-94A7-4030FBD11604Q26738384-5FD76D79-7BE2-432F-B847-6BD6B6A1ACABQ26747276-DB8F9AF3-1001-427F-952C-550D2420334FQ26747703-8B62305F-B4B5-4537-9FD5-37F9FA012C46Q26778500-4B1D2CF0-BE4F-419D-A5C7-5C5BBF9AA788Q26786932-9A2C31A1-B695-4248-83B9-6D6DB5C20D5CQ26799467-FBA2914C-2AFE-45E9-881D-3519609A46B0Q26851392-17926EEC-3A4A-4EE2-85F0-E736F79DC934Q26858819-AAC4CDDD-44AC-47A4-96E4-7C3C5320CD86Q27015079-7992DF04-6A4B-4AAA-8DE2-D92E0D7F4083Q27022941-F25CA634-5F5E-48CC-987D-AE1A6E666B0CQ27024212-9ED36D25-0E4E-4643-AF56-AC5A94E6E4C5Q27612411-CA791579-C51F-4094-8680-FA60A51FC263Q27671787-E1BAC261-0552-4053-B987-897ACE557D2EQ27675915-7C37A1C3-AEED-4F01-8E42-BCCFE18DC225Q27851440-167F73CA-4D6B-4B18-A29C-57460FC765D0Q27851588-CEB83C76-A1A3-43DF-A613-66A05362E33DQ27851589-28C27E21-7396-4355-89C5-69C0F404CE4BQ27851591-E0B2A6DA-6D51-4CFF-B267-1EEBD8CD257DQ27851681-ABBAC6B0-2D1E-4B7E-AA1B-22ED83885EAEQ27851684-A8775553-932E-4548-8B92-F6F0BAE51BECQ27852211-309D4C9D-7409-4596-A0C7-7E6F1D361251Q27853157-33EABF3E-E93A-4D6A-B0DD-22AE6A797DB5Q27853323-66F0E957-F25A-4F8A-B474-D768E8E295E8Q28069836-2AF66345-C2C5-48A4-B6D3-C66A22DD01DFQ28071903-CCA60D41-27FE-47FE-B50F-388C18AB8B85Q28083386-835915A8-EE7F-4B7A-9B0C-6CF9FCAB1851Q28083711-27264AC0-84DA-4B60-A080-7B694CEA0445Q28267124-9493EB4C-911F-49F0-8E05-1C1FDB0E9DBFQ28393324-BE7F4DA4-6C05-46DE-89CA-6133719DA5F1Q28546245-34BF2E04-E600-49BC-A12C-B10D067E37E2Q28547121-43CF70F6-F8FC-4662-938F-5DCA7B4CD822Q28553147-EE0809D9-4E5F-478E-8E96-4C8602A6F248Q29615472-50E8D956-618F-4B9B-A690-9F11443ECB79Q30502341-70170EAF-6C18-4717-9E97-3BB2CA21417B
P2860
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Cytoreductive antitumor activi ...... naplastic large-cell lymphoma.
@ast
Cytoreductive antitumor activi ...... naplastic large-cell lymphoma.
@en
Cytoreductive antitumor activi ...... naplastic large-cell lymphoma.
@nl
type
label
Cytoreductive antitumor activi ...... naplastic large-cell lymphoma.
@ast
Cytoreductive antitumor activi ...... naplastic large-cell lymphoma.
@en
Cytoreductive antitumor activi ...... naplastic large-cell lymphoma.
@nl
prefLabel
Cytoreductive antitumor activi ...... naplastic large-cell lymphoma.
@ast
Cytoreductive antitumor activi ...... naplastic large-cell lymphoma.
@en
Cytoreductive antitumor activi ...... naplastic large-cell lymphoma.
@nl
P2093
P3181
P1476
Cytoreductive antitumor activi ...... naplastic large-cell lymphoma.
@en
P2093
Barbara Mroczkowski
Gerrit Los
Gordon R Alton
Helen Y Zou
James G Christensen
Joseph H Lee
Maria E Arango
Scott R McDonnell
Shinji Yamazaki
P304
P3181
P356
10.1158/1535-7163.MCT-07-0365
P433
P577
2007-12-01T00:00:00Z